Cancer Biopsy Market Expected to Receive Greater Traction As Manufacturers’ Contribution Swells

 Cancer Biopsy Market Growth & Trends

The global cancer biopsy market size is expected to reach USD 44.51 billion by 2027, according to a new report by Grand View Research, Inc. It is projected to expand at a CAGR of 11.13% from 2021 to 2027. The expanding landscape of molecular medicine paved the way for the development of new devices for the molecular characterization of cancers. Thus, increasing adoption and product approvals for liquid biopsies are expected to drive the overall market.

The kits and consumables product segment is expected to maintain its lead in the years to come. Acknowledging this trend, various market players have invested in the development of novel kits in order to expand their biopsy kits portfolio. For instance, in April 2021, Sysmex Europe GmbH, along with Sysmex Inostics GmbH, introduced Plasma-SeqSensei liquid biopsy research use only (RUO) kits in EMEA.

The tissue biopsies segment emerged as the dominant type segment in 2020. Shortcomings of liquid biopsies such as the lack of robust efficacy evaluations and associated high costs are currently bridged by tissue biopsies. This has made tissue biopsy a gold-standard procedure in the present diagnostic scenario.

Liquid biopsies are expected to offer lucrative opportunities in the field of oncology-based personalized medicine and genomic data analysis. Recognizing the potential of these tests, the regulatory bodies are actively supporting the commercialization of these products and increasing the use of these assays in clinics. For instance, in November 2020, the FoundationOne Liquid CDx test was approved by the U.S. FDA as a companion diagnostic device for multiple cancers.

The liquid biopsies segment is expected to expand at an exponential rate in the coming years, wherein increasing investments and strategic initiatives by companies involved in biopharmaceutical manufacturing and genomic data analysis are expected to play a central role. The emerging companies are inclined towards collaborating with well-established industry participants, including SOPHiA Genetics, QIAGEN Bioinformatics, Agilent Technologies, and Fabric Genomics. This trend is further expected to favor the overall market growth.

Key players are focusing on developing novel biopsy platforms, set to achieve business expansion, further contributing to the revenue generation in the market. In March 2021, Quick-Core Auto Biopsy System for biopsy procedure soft tissue biopsy was launched by IZI Medical Products. This product is fully automated, which is built based on the company’s proprietary semi-automatic system, Quick-Core.

Request a free sample copy or view report summary: Cancer Biopsy Market Report

Cancer Biopsy Market Report Highlights

• By product, kits and consumables accounted for the largest revenue share in 2020 and are anticipated to maintain its lead throughout the forecast period. The adoption of kits and consumables is expected to increase owing to the significant transition from tumor to liquid biopsy
• Based on type, tissue biopsies are still considered to be a mainstay of biopsies and are largely adopted across various diagnosis applications. Additionally, tumor biopsy is most adopted for diagnosis on individual levels, along with monitoring the effects of an ongoing oncology treatment
• North America held the largest revenue share in 2020 owing to the concentrated pool of active organizations and cancer foundations. The strong network of government organizations and private cancer foundations in the U.S. has made significant contributions to the regional revenue generation capacity
• In terms of application, breast cancer dominated the global market in 2020 and is expected to maintain its lead throughout the forecast period. Open surgical biopsy is considered to be a reference standard for the evaluation of patients with a suspicious breast lesion. This is attributed to its proven accuracy in diagnosing breast lesions, further contributing to the revenue generated by this segment

Access Press Release@ https://www.grandviewresearch.com/press-release/global-cancer-biopsy-market

Cancer Biopsy Market Segmentation

Grand View Research has segmented the global cancer biopsy market on the basis of product, type, application, and region:

Cancer Biopsy Product Outlook (Revenue, USD Million, 2018 - 2027)

• Instruments
• Kits and Consumables
• Services

Cancer Biopsy Type Outlook (Revenue, USD Million, 2018 - 2027)

• Tissue Biopsies
  • Needle Biopsies
    • Fine Needle Aspiration (FNA)
    • Core Needle Biopsy (CNB)
  • Surgical Biopsies
• Liquid Biopsies
• Others

Cancer Biopsy Application Outlook (Revenue, USD Million, 2018 - 2027)

• Breast Cancer
• Colorectal Cancer
• Cervical Cancers
• Lung Cancers
• Prostate Cancers
• Skin Cancers
• Blood Cancers
• Kidney Cancers
• Liver Cancers
• Pancreatic Cancers
• Ovarian Cancers
• Others

Cancer Biopsy Regional Outlook (Revenue, USD Million, 2018 - 2027)

• North America
  • US.
  • Canada
• Europe
  • Germany
  • UK.
  • France
  • Spain
  • Italy
• Asia Pacific
  • Japan
  • China
  • India
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia

List of Key Players of Cancer Biopsy Market

• Qiagen N.V.
• Illumina, Inc.
• ANGLE Plc
• BD (Becton, Dickinson And Company)
• Myriad Genetics
• Hologic, Inc.
• Biocept, Inc.
• Thermo Fisher Scientific, Inc.
• Danaher
• Hoffmann-La Roche Ltd.
• Lucence Diagnostics Pte. Ltd.
• GRAIL, Inc.
• Guardant Health
• Exact Sciences Corporation
• Freenome Holdings, Inc.
• Biodesix (Integrated Diagnostics)
• Oncimmune
• Epigenomics AG
• HelioHealth (Laboratory for Advanced Medicine)
• Genesystems, Inc. (Genesys Biolabs)
• Chronix Biomedical, Inc.
• Personal Genome Diagnostics Inc.
• Natera, Inc.
• Personalis Inc.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.